Company Encyclopedia
View More
name
Pulmonx
LUNG.US
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
1.407 T
LUNG.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking89/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-73.73%E
    • Profit Margin-61.91%E
    • Gross Margin74.65%A
  • Growth ScoreC
    • Revenue YoY15.59%B
    • Net Profit YoY0.62%C
    • Total Assets YoY-17.40%E
    • Net Assets YoY-36.08%E
  • Cash ScoreC
    • Cash Flow Margin-161.51%D
    • OCF YoY15.59%B
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreD
    • Gearing Ratio56.59%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Lehman Surrenders 10,278 Of Pulmonx Corp [LUNG]

    Lehman David Aaron, an officer of Pulmonx Corp [LUNG], surrendered 10,278 shares at $1.57 each on December 1, 2025, to cover option exercise costs and/or tax liabilities. His remaining direct holdings are 252,992 shares.

    Reuters·
    US
    LUNG
    +13.23%
    Reuters·
    US
    LUNG
    +13.23%

    Pulmonx Grants 1.6 Million Equity Awards to New Executives Under Inducement Plan

    Pulmonx Corporation has granted 1,625,000 shares of common stock to new executives, including CFO and COO Derrick Sung, under an inducement plan. Sung received a performance stock unit award for up to 400,000 shares, with vesting based on time and performance conditions. Vesting requires Sung's continued employment and the company's stock reaching a specified average closing price. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    LUNG
    +13.23%
    Reuters·
    US
    LUNG
    +13.23%

    08:04 ET Virginia Cancer Specialists Expands Lung Cancer and Thoracic Oncology Program, Welcomes Thoracic Surgeon Christopher R. Johnson, MD

    Virginia Cancer Specialists (VCS) has expanded its Lung Cancer and Thoracic Oncology Program by welcoming Dr. Christopher R. Johnson, a board-certified thoracic surgeon with over a decade of experience. Dr. Johnson will practice in Fairfax and has privileges at Inova Fairfax Hospital and VHC Arlington. His expertise in robotic thoracic surgery and minimally invasive techniques will enhance VCS's multidisciplinary team, benefiting patients across Northern Virginia. VCS is the largest private cancer practice in Northern Virginia, offering comprehensive cancer care and participating in clinical trials through the US Oncology Network.

    prnewswire·
    US
    JNJ
    -1.39%
    US
    LUNG
    +13.23%
    prnewswire·
    US
    JNJ
    -1.39%
    US
    LUNG
    +13.23%

    European Commission Authorizes First Treatment For Serious Chronic Lung Disease

    The European Commission has authorized 'brensocatib' for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. This addresses a significant unmet medical need, as NCFB affects 400,000 to 3 million people in the EU. The authorization follows a positive assessment by the European Medicines Agency, though the drug requires a prescription and may have side effects.

    rttnews·
    US
    LUNG
    +13.23%
    rttnews·
    US
    LUNG
    +13.23%

    05:03 ET World COPD Day: Lung Association Offers Free Access to Lung Health Navigators to People with COPD Nationwide

    On World COPD Day, the American Lung Association highlights its free Lung Health Navigator program, offering personalized support to COPD patients nationwide, especially in rural areas. Licensed healthcare professionals provide guidance on treatment, insurance, and lifestyle changes. The initiative is part of the "Living Well with COPD" campaign, supported by major pharmaceutical companies. The program aims to improve access to care and quality of life for over 11 million Americans affected by COPD.

    prnewswire·
    US
    LUNG
    +13.23%
    prnewswire·
    US
    LUNG
    +13.23%
    © 2025 Longbridge｜Disclaimer